HSK 31679
Alternative Names: HSK-31679Latest Information Update: 27 Feb 2026
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antihyperlipidaemics; Antithrombotics
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypercholesterolaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 16 Jan 2026 Haisco Pharmaceutical completes a phase IIb trial in Non-alcoholic steatohepatitis in China (PO) (NCT06168383)
- 05 Jun 2024 Efficacy and adverse event data from a phase II trial in Hypercholesterolaemia presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
- 01 Mar 2024 Haisco Pharmaceutical Group completes a phase II trial in Hypercholesterolaemia in China (PO) (NCT05795517)